Dr Lindsay Rosenwald | Lindsay Rosenwald Success & Achievements

Terminal stage prostate cancer sufferers, who had no more beneficial effect from chemotherapy, were treated with Johnson & Johnson’s (JNJ) test preparation abiraterone which prolonged their survival for about four months in comparison with the people suffering from the same disease but treated with a placebo, in accordance with the results concerning a phase III research analysis provided at the European Society of Medical Oncology (ESMO) annual meeting on October 2009.

Johnson & Johnson reported the highest positive research returns from the analysis of abiterone treatment the previous month and declared firm intention to find the preparation’s commendation. Minute descriptions of the results, along with the numerous advantages of abiraterone treatment indisputably prolonging lives, were introduced at the ESMO annual conference.

The phase III research recruited 1,195 prostate cancer sufferers, treating them at random with abiterone acetate along with the steroid prednisone or a placebo along with prednisone. Every sufferer participating in the research had a diagnosis of metastatic, terminal stage prostate cancer with sarcomas no more beneficially affected by hormonal therapy or chemotherapy, namely the most famous and generally used preparation Taxotere.

The sufferers instituted abiraterone therapy showed 35% increase of chances to survive in comparison with the sufferers taking a placebo. The average statistics data on people surviving showed the results as follows: the sufferers treated with abiraterone survived for 14.8 months, and 10.9 of those treated with a placebo, which makes abiraterone about four months more effective in survival.

Physicians normally start prostate cancer sufferers treatment through hormonal therapy so as to cease testosterone producing and to delay sarcoma development, however many of the prostate cancers come to be refractory to such a therapy and begin growing anew.

The original research introduced at the ESMO congress and funded by leading investors, including Lindsay Rosenwald, MD, demonstrated the abiraterone usage on prostate cancer sufferers who have no more beneficial effect from hormone therapy and chemotherapy – the third line sufferers in hopeless condition. However Johnson & Johnson is researching and analyzing the effect of abiraterone usage on the sufferers who show no more beneficial effect from hormone therapy still not yet subjected to chemotherapy.

Prostate cancer immunotherapy Provenge

Aberaterone’s primary rivalry seems to have started due  Sanofi-Aventis’ (SNY) Jevtana, commended sooner current year for hopeless third line prostate cancer sufferers. In the middle of the phase III research, Jevtana demonstrated average statistics data on people surviving with treatment for 15.1 months in comparison with 12.7 months for the sufferers treated with different chemotherapy preparation mitoxantrone.

Medivation (MDVN) together with partner Astellas are working out MDV3100, a prostate cancer preparation which in its effect does not differ much from abiraterone. Phase III researches have already started.

About Abiraterone Acetate

Abiraterone has been licensed by Cougar Biotechnology and acquired by Johnson & Johnson after its phase II clinical trial for a late stage drug candidate for the treatment of prostate cancer. Cougar has been funded by several leading investors, including Dr. Lindsay Rosenwald, as a promising first-in-class compound tested in patients with advanced castrate-resistant prostate cancer, who have yet to receive their chemotherapy.

J&J filed its marketing applications in late 2010. If approved, abiraterone acetate will be allowed for distribution in early 2011 in the United States and Europe with the rest of the world to follow.

It has been almost twenty years since Dr. Lindsay Rosenwald started his career in medicine and the biosciences, in those years he has become known as a man of great advancement in biotechnology. His work with the sciences of medicine has earned him honor, and rightly so. Since Dr. Rosenwald started his career he has formed over forty companies, biotechnical and pharmaceutical in nature and gathered almost a billion dollars for the resources needed to finance biotechnical companies that have shown great promise.

Dr. Lindsay Rosenwalld is of course best known for his being an investment banker and venture capitalist, but also as a hedge fund manager. His first company, has provided many smaller biotechnical companies with the needed resources to further their work and develop some of the most beneficial drugs being tested and used today. Dr. Rosenwald gives his backing to companies where he sees the most potential therefore he is being a good steward of finances while helping humanity.

Lindsay graduated from Abington High School in 1973 and went on to pursue his career in medicine at Pennsylvania State University. He was a member of the honor society for business school known as Beta Gamma Sigma while he attended. After graduating there he was awarded a Bachelors of Science in finance degree which was in 1977. Lindsay then decided to pursue his medical interests at Temple University School of Medicine. He graduated there with a medical degree in 1983.

Deciding to begin his medical career, Dr. Lindsay Rosenwald enrolled for an internship at Abington Hospital and following that moved into private practice until 1986. It was then that he made a move that would seem outlandish to some, he went to Wall Street to become an analyst as well as physician.

By 1991 Dr. Rosenwald had now formed his group, in which he also had his first company. They provide funding to companies in the biotechnology sector that are looking to develop treatment options that are breakthrough in nature,that includes helping with their start ups and research for development.

Dr. Lindsay Rosenwald is one of The Most Prolific Leaders in the biotechnology field. With his humongous experience in starting up the companies and investing in small ventures, he has become the most influential leader in the Biotechnology market. He helped a lot of new companies by funding in the initial stages. He believes in funding new ventures and small companies as he feels that the small companies would change the status quo in the biotechnology market.

Dr. Lindsay also handles a wide range of financial portfolio. His portfolio includes venture capital, hedge fund and capital assets. This financial portfolio made him an influential person in the Wall Street, New York. Once he moved to Wall Street, New York, he started concentrating on the advanced research and development of biotechnology. His first venture  is one of the group companies that help in fund rising for the portfolio companies. With the company, Dr. Lindsay Rosenwald started numerous companies that are into advanced drug development and clinical research.

Dr. Lindsay is the founder of Rosenwald Foundation, which is a charitable foundation that helps most of the professionals who plan to excel in the biotechnology market. This is considered to be one of the most influential and helpful foundation in the biotechnology market. Apart from this, Lindsay has been serving as the director for several public and private limited companies. With the 20 years of experience, he helped a lot of MBAs, PhDs, to excel in the biotechnology field.

Dr. Rosenwald is the founder of a group of companies which are actively involved in the clinical research and drug development.  This is the reason why, Lindsay is considered to be the most successful and influential leader in the biotechnology and finance. His contributions to the biotechnology are incredible and humongous. Dr Lindsay is also known for getting the quick approvals form FDA to market the drugs.

Dr. Lindsay Rosenwald completed his Bachelor of Science and a Finance degree for Pennsylvania University in 1972 and later on, he moved to the Templeton School of Medicine to get his medical degree. With the finance and medical degree in hand, he started his own medical practice and ran it successfully for two years. This small medical practice is said to be the first entrepreneurial venture for Lindsay.